KBC Group NV grew its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 768.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 32,935 shares of the medical research company’s stock after buying an additional 29,143 shares during the quarter. KBC Group NV’s holdings in Bio-Rad Laboratories were worth $24,568,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Berman Capital Advisors LLC raised its position in shares of Bio-Rad Laboratories by 20.6% during the 3rd quarter. Berman Capital Advisors LLC now owns 82 shares of the medical research company’s stock valued at $61,000 after buying an additional 14 shares in the last quarter. Seeyond raised its position in shares of Bio-Rad Laboratories by 0.5% during the 2nd quarter. Seeyond now owns 4,219 shares of the medical research company’s stock valued at $2,718,000 after buying an additional 19 shares in the last quarter. Rafferty Asset Management LLC raised its position in shares of Bio-Rad Laboratories by 5.2% during the 2nd quarter. Rafferty Asset Management LLC now owns 446 shares of the medical research company’s stock valued at $287,000 after buying an additional 22 shares in the last quarter. Creative Planning raised its position in Bio-Rad Laboratories by 2.1% in the 3rd quarter. Creative Planning now owns 1,080 shares of the medical research company’s stock worth $806,000 after purchasing an additional 22 shares during the period. Finally, JustInvest LLC raised its position in Bio-Rad Laboratories by 3.7% in the 2nd quarter. JustInvest LLC now owns 652 shares of the medical research company’s stock worth $420,000 after purchasing an additional 23 shares during the period. Hedge funds and other institutional investors own 63.89% of the company’s stock.
Separately, Zacks Investment Research lowered shares of Bio-Rad Laboratories from a “strong-buy” rating to a “hold” rating and set a $791.00 price objective on the stock. in a research report on Wednesday, September 29th.
Bio-Rad Laboratories stock opened at $628.23 on Friday. Bio-Rad Laboratories, Inc. has a 1-year low of $545.00 and a 1-year high of $832.70. The firm has a market capitalization of $18.80 billion, a P/E ratio of 2.85 and a beta of 0.86. The company’s 50-day moving average is $734.38 and its 200 day moving average is $742.03.
Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, October 28th. The medical research company reported $3.71 EPS for the quarter, topping the Zacks’ consensus estimate of $2.30 by $1.41. The business had revenue of $747.00 million for the quarter, compared to analyst estimates of $670.36 million. Bio-Rad Laboratories had a net margin of 223.47% and a return on equity of 4.19%. The company’s quarterly revenue was up 15.4% compared to the same quarter last year. During the same period last year, the company posted $3.00 earnings per share. On average, equities analysts predict that Bio-Rad Laboratories, Inc. will post 15.33 EPS for the current year.
Bio-Rad Laboratories Profile
Bio-Rad Laboratories, Inc engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments.
Featured Article: What are the reasons investors use put options?
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.